{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:21:50Z","timestamp":1793413310090,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["202102310402, 182102311171, 19A320045, 2020SP0102, 2020BP0112, 2020BP0117, 2020BP0201, 20-21ZY1044"],"award-info":[{"award-number":["202102310402, 182102311171, 19A320045, 2020SP0102, 2020BP0112, 2020BP0117, 2020BP0201, 20-21ZY1044"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This study aimed to establish a cell-based assay (CBA) for the detection of agrin antibodies (Agrin-Ab) to explore the clinical features of agrin antibody-positive Chinese patients with myasthenia gravis (Agrin-MG). We developed a CBA based on the human full-length agrin protein expressed in HEK293T cells for the reliable and efficient detection of Agrin-Ab. Clinical data and serum samples were collected from 1948 MG patients in 26 provinces in China. The demographic and clinical features of Agrin-MG patients were compared with those of other MG patient subsets. Eighteen Agrin-MG cases were identified from 1948 MG patients. Nine patients were Agrin-Ab positive, and nine were AChR-Ab and Agrin-Ab double-positive (Agrin\/AChR-MG). Eleven (61.11%) patients were males older than 40 years of age. The initial symptom in 13 (81.25%) cases was ocular weakness. Occasionally, the initial symptom was limb-girdle weakness (two cases) or bulbar muscle weakness (one case). Agrin-MG patients demonstrated slight improvement following treatment with either acetylcholinesterase inhibitor or prednisone; however, the combination of the two drugs could effectively relieve MG symptoms. In China, Agrin-MG demonstrated seropositivity rates of 0.92%. These patients were commonly middle-aged or elderly men. The patients usually presented weakness in the ocular, bulbar, and limb muscles, which may be combined with thymoma. These patients have more severe diseases, although the combination of pyridostigmine and prednisone was usually effective in relieving symptoms.<\/jats:p>","DOI":"10.3389\/fimmu.2021.753247","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T06:18:48Z","timestamp":1638944328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis"],"prefix":"10.3389","volume":"12","author":[{"given":"Shumin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International Consensus Guidance for Management of Myasthenia Gravis","volume":"4","author":"Sanders","year":"2016","journal-title":"Am Acad Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature","volume":"1","author":"Deenen","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46","article-title":"A Systematic Review of Population Based Epidemiological Studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1016\/j.lanwpc.2020.10","article-title":"Incidence, Mortality, and Economic Burden of Myasthenia Gravis in China: A Nationwide Population-Based Study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to Acetylcholine Receptor in Myasthenia Gravis Prevalence, Clinical Correlates, and Diagnostic Value","volume":"5","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/BF00313297","article-title":"Myasthenia Gravis: Antibodies to Acetylcholine Receptor in Ocular Myasthenia Gravis","volume":"6","author":"Oda","year":"1981","journal-title":"J Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 Autoantibodies Cause Myasthenia Gravis by Inhibiting Binding Between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/85520","article-title":"Auto-Antibodies to the Receptor Tyrosine Kinase MuSK in Patients With Myasthenia Gravis Without Acetylcholine Receptor Antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-012-1159-x","article-title":"The High Frequency and Clinical Feature of Seronegative Myasthenia Gravis in Southern China","volume":"34","author":"Feng","year":"2013","journal-title":"Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to Lipoprotein-Related Protein 4 in Patients With Double-Seronegative Myasthenia Gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol (Chicago)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Myasthenia Gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2018.01.015","article-title":"Induction of Anti-Agrin Antibodies Causes Myasthenia Gravis in Mice","volume":"373","author":"Yan","year":"2018","journal-title":"Neuroscience"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to Agrin in Myasthenia Gravis Patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26985","article-title":"Clinical Features of LRP4\/agrin-Antibody\u2013Positive Myasthenia Gravis: A Multicenter Study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrm1074","article-title":"New Insights Into the Roles of Agrin","volume":"4","author":"Bezakova","year":"2003","journal-title":"Nat Rev Mol Cell Bio"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2006.10.012","article-title":"Neural Agrin: A Synaptic Stabiliser","volume":"39","author":"Ngo","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671","article-title":"Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells-Basel"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.06.015","article-title":"Identification of an Agrin Mutation That Causes Congenital Myasthenia and Affects Synapse Function","volume":"85","author":"Huz\u00e9","year":"2009","journal-title":"Am J Hum Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-011-1132-4","article-title":"LG2 Agrin Mutation Causing Severe Congenital Myasthenic Syndrome Mimics Functional Characteristics of non-Neural (Z\u2013) Agrin","volume":"131","author":"Maselli","year":"2012","journal-title":"Hum Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577076","article-title":"A Novel MuSK Cell-Based Myasthenia Gravis Diagnostic Assay","volume":"337","author":"Han","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A Comprehensive Analysis of the Epidemiology and Clinical Characteristics of Anti-LRP4 in Myasthenia Gravis","volume":"4","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13979","article-title":"Clinical Analysis of Chinese Anti-Low-Density-Lipoprotein-Receptor-Associated Protein 4 Antibodies in Patients With Myasthenia Gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur J Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s1474-4422(03)00306-5","article-title":"Seronegative Generalised Myasthenia Gravis: Clinical Features, Antibodies, and Their Targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","article-title":"Use of Cell-Based Assays in Myasthenia Gravis and Other Antibody-Mediated Diseases","volume":"270","author":"Rodriguez Cruz","year":"2015","journal-title":"Exp Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The Different Roles of the Thymus in the Pathogenesis of the Various Myasthenia Gravis Subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional Activities of Autoantibodies to Acetylcholine Receptors and the Clinical Severity of Myasthenia Gravis","volume":"6","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e114060","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated Acetylcholine Receptor Antibody-Concentrations and Association to Clinical Myasthenia Gravis Development","volume":"9","author":"Heldal","year":"2014","journal-title":"PLoS ONE"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2018.01.042","article-title":"Anti-MuSK Antibodies: Correlation With Myasthenia Gravis Severity","volume":"9","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.052415","article-title":"The Features of Myasthenia Gravis With Autoantibodies to MuSK","volume":"76","author":"Lavrnic","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66039","article-title":"Antibodies Against Low-Density Lipoprotein Receptor\u2013Related Protein 4 Induce Myasthenia Gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 Antibodies to Acetylcholine Receptors in \u2018Seronegative\u2019 Myasthenia Gravis\u2020","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical Comparison of Anti-MuSK-Vs Anti-AChR-Positive and Seronegative Myasthenia Gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-Agrin Autoantibodies in Myasthenia Gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25438","article-title":"Agrin and Low-Density Lipoprotein-Related Receptor Protein 4 Antibodies in Amyotrophic Lateral Sclerosis Patients","volume":"55","author":"Rivner","year":"2017","journal-title":"Muscle Nerve"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-Specific Cell-Based Assay Detects Potentially Pathogenic MuSK-Abs in Seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.753247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T06:18:51Z","timestamp":1638944331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.753247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2021.753247"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.753247","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"article-number":"753247"}}